SHENZHEN, China, July 17 /Xinhua-PRNewswire-FirstCall/ -- Mindray Medical International Limited (NYSE: MR), a leading developer, manufacturer and marketer of medical devices worldwide has announced today that it will highlight all of its marketed in-vitro diagnostic products as well as unveil three new units and reagents at the 2008 Annual American Association for Clinical Chemistry (AACC) conference. The conference will be attended by Mr. Jie Liu, Executive Vice President of International Sales & Marketing and Mr. Wei Wang, Vice President of Research and Development.
Mindray will showcase its entire line of in-vitro diagnostic products at the conference, along with three demo units: the BC-5300 and BC-5380, both of which are Hematology Analyzers, the BA-88A, a Semi-automatic Biochemistry Analyzer, and the first five reagents for the Biochemistry Analyzer. All products are expected to enter the international market in the second half of 2008.
"Mindray’s presence at this conference speaks volumes about the direction in which the company is heading," commented Mr. Li Xiting, Mindray’s President and Co-Chief Executive Officer. "Presenting at the AACC conference allows us to showcase our high quality products, and demonstrate their efficacy to the medical community."
Mindray’s products will be on display at AACC booth 825 in Hall A. The 60th Annual AACC conference will take place from July 29 through July 31 at the Washington Convention Center in Washington D.C. AACC is an international society comprised of medical professionals with an interest in clinical chemistry, clinical laboratory science, and laboratory medicine. Founded in 1948, the society has over 9,000 members and is headquartered in Washington, D.C.
About Mindray
Mindray is a leading developer, manufacturer and marketer of medical devices worldwide. Established in 1991, Mindray offers a broad range of products across three primary business segments: patient monitoring & life support products, in-vitro diagnostic products and medical imaging systems. Mindray is globally headquartered in Shenzhen, China, with U.S. headquarters in Mahwah, New Jersey. Mindray also has another 12 international sales and service offices in Amsterdam, Frankfurt, Istanbul, London, Mexico City, Moscow, Mumbai, Paris, Sao Paolo, Seattle, Toronto and Vancouver.
For more information, please visit http://www.mindray.com .
Safe Harbor Statement
This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "confident" and similar statements. Statements that are not historical facts, including statements about Mindray’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. Information regarding these risks and uncertainties is included in our public filings with the Securities and Exchange Commission. All information provided in this press release is as of July 17, 2008, and Mindray undertakes no duty to update such information, except as required under applicable law.
For investor and media inquiries, please contact:
In the U.S:
Evan Smith,
FD
Tel: +1-212-850-5606
Email: evan.smith@fd.com
John Capodanno,
FD
Tel: +1-212-850-5705
Email: john.capodanno@fd.com
In China:
Susan Du
Mindray Medical International Limited
Tel: +86-755-2658-2518
Email: Susan.Du@Mindray.com
